View:
July 11, 2024
Jean-Philippe Kouakou-Zebouah
Chief Financial Officer
Vida Ventures, LLC
40 Broad Street, Suite 201
Boston, MA 02109
Re: Vida Ventures, LLC
Kyverna Therapeutics, Inc.
Schedule 13D Filed By Vida Ventures, LLC et al.
Filed May 3, 2024
File No. 005-94441
Dear Jean-Philippe Kouakou-Zebouah:
We have reviewed the above-captioned filing and have the following
comment.
Please respond to this letter by amending the filing or by providing the
requested
information. If you do not believe our comment applies to your facts and
circumstances or that an
amendment is appropriate, please advise us why in a response letter.
After reviewing any amendment to the filing and any information provided
in response to
this comment, we may have additional comments.
Schedule 13D Filed May 3, 2024
General
1. We note the date of the event reported as requiring the filing of the
Statement was
February 12, 2024. Rule 13d-1(a) of Regulation 13D-G requires the filing
of a Schedule
13D within five business days after the date beneficial ownership of
more than five
percent of a class of equity securities specified in Rule 13d-1(i)(1)
was acquired. Based on
the February 12, 2024 event date, the Schedule 13D submitted on May 3,
2024 was not
timely filed. Please advise us why the Schedule 13D was not filed within
the required five
business days after the date of the acquisition.
July 11, 2024
Page 2
We remind you that the filing persons are responsible for the accuracy
and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please direct any questions to Shane Callaghan at 202-551-6977 or
Nicholas Panos at
202-551-3266.
Sincerely,
Division of
Corporation Finance
Office of Mergers &
Acquisitions